Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

China flag China · Delayed Price · Currency is CNY
56.88
-1.96 (-3.33%)
Mar 3, 2026, 3:04 PM CST
0.34%
Market Cap 46.33B
Revenue (ttm) 6.56B
Net Income (ttm) 612.15M
Shares Out 855.14M
EPS (ttm) 0.71
PE Ratio 79.65
Forward PE 56.87
Dividend 0.30 (0.51%)
Ex-Dividend Date Jun 17, 2025
Volume 9,648,132
Average Volume 11,817,801
Open 60.18
Previous Close 58.84
Day's Range 56.70 - 60.18
52-Week Range 41.61 - 71.90
Beta 0.70
RSI 38.62
Earnings Date Mar 31, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,251
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300347
Full Company Profile

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial Statements

News

Hangzhou Tigermed Consulting Co., Ltd (HNGZY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-16. The following slide deck was published by Hangzhou Tigermed Consulting Co., Ltd in conjunction with this event.

6 weeks ago - Seeking Alpha